Friday, April 2, 2021

Mirati Therapeutics Names New Board Member

San Diego-based Mirati Therapeutics said this week that it has added Ms. Shalini Sharp as a new independent director at the targeted oncology company. Sharp was most recently Chief Financial Officer (CFO) at Ultragenyx, and also served at Agenus, McKinsey & Company, and Goldman Sachs. She also serves on the boards of Neurocrine Biosciences, Precision Biosciences, Sutro Biopharma and TB Alliance.